US EditionPublished • loading... • Updated
Novo Nordisk (CPH: NOVO-B): It's not all smooth sailing for the US$180bn company behind obesity drug Ozempic
Summary by Stocks Down Under
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Novo Nordisk (CPH: NOVO-B): It's not all smooth sailing for the US$180bn company behind obesity drug Ozempic
Not many 100-year old healthcare stocks see a sudden 30% jump in sales in one year and become the largest capitalised company on their entire continent but Novo Nordisk (CPH: NOVO-B) is one such stock that did just that. Its a Danish drug maker that is behind weight loss drugs Ozempic and Wegovy. For much…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
